Additionally, Smit and colleagues reported data from the cohort of DESTINY-Lung01 which evaluated T-DXd in NSCLC patients with activating HER2 mutations, on which 90% were relegated to the kinase domain [146] With most patients previously receiving both chemotherapy and ICI, an impressive ORR of 62% (26/42) was seen, for which the median duration was not reached at the time of data cutoff (median follow-up eight months). The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.